NNVC / NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

NanoViricides (NYSE-A:NNVC) said it has sufficient funds to complete its ongoing Phase 1a/1b clinical trial of its lead drug candidate NV-CoV-2 based more_horizontal

SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. An more_horizontal

NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing succes more_horizontal

As a war often accelerates technological innovation, the recent coronavirus pandemic in 2020 provided a big spur to advancements in biotechnology, wit more_horizontal

NanoViricides Inc (NYSE-A:NNVC) has announced the promising efficacy of its antiviral drug candidate NV-387 in combating Respiratory Syncytial Virus more_horizontal

NanoViricides Inc (NYSE-A:NNVC) has announced that the clinical trial of its broad-spectrum antiviral drug, NV-CoV-2, is progressing satisfactorily. T more_horizontal

NanoViricides Inc (NYSE-A:NNVC) has announced that clinical trials for its broad-spectrum antiviral drug NV-CoV-2 commenced on June 17, 2023. The tri more_horizontal

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan more_horizontal